Editas Medicine (NASDAQ:EDIT) Stock Breaks Below 50-Day Moving Average - Here's Why
Editas Medicine (NASDAQ:EDIT) shares have fallen below their 50-day moving average, trading at $2.57, below the $2.85 average. Despite the stock's recent dip, analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $5.80. The company also recently exceeded quarterly earnings expectations, reporting a smaller loss and higher revenue than projected.
Revenue per share of Editas Medicine, Inc. – HAN:8EM
This page provides financial information for Editas Medicine, Inc. (8EM) on the Hannover Stock Exchange, specifically focusing on its revenue per share. It indicates that the market is currently closed with no trades. The content highlights the financial overview, documents, news, community, and forecasts related to the company.
Editas Medicine, Inc. Earnings and Revenue – HAN:8EM
Editas Medicine, Inc. (HAN:8EM) reported earnings of -0.13 EUR per share, significantly beating the estimated -0.24 EUR by 44.55%. Revenue for the last quarter reached 10.41M EUR, far exceeding the 2.49M EUR estimate. Analysts anticipate -0.17 EUR in EPS and 4.00M EUR in revenue for the next quarter.
Editas Medicine (EDIT) Short Interest & Short Float | Updated Sep 2026 $EDIT
This article provides an update on Editas Medicine's (EDIT) short interest and short float as of September 2026. It details that Editas Medicine had 29.96 million shares sold short, representing 20.13% of its public float, which is a slight decrease from the previous month. The article also explains key short interest metrics like days to cover and compares EDIT's short interest to its competitors in the biotechnology industry.
This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Several top Wall Street analysts have upgraded their ratings for key companies. Notable upgrades include Microsoft (MSFT) from Hold to Buy by Stifel, Graphic Packaging Holding Co (GPK) from Neutral to Overweight by JP Morgan, Editas Medicine Inc (EDIT) from Neutral to Buy by Guggenheim, and Lakefront Biotherapeutics NV (LKFT) from Sector Perform to Outperform by RBC Capital. These changes reflect a more bullish outlook on these stocks, with corresponding adjustments to price targets.
Editas stock raised to Buy at Guggenheim (EDIT:NASDAQ)
Guggenheim has upgraded Editas Medicine (EDIT) stock to Buy from Neutral. The upgrade is based on the potential of the company's hyperlipidemia therapy, EDIT-401, which offers a novel gene editing approach for treating severely high blood cholesterol. Editas is currently preparing to advance this therapy.
Guggenheim upgrades Editas Medicine to Buy, sets $5 price target
Guggenheim has upgraded Editas Medicine (EDIT) to a Buy rating, setting a $5 price target, which represents a 71.2% upside from its previous close. This upgrade is based on positive preclinical data for their drug EDIT-401, which targets severe hypercholesterolemia, and the drug's potential to address a significant market with its one-time treatment approach.
Guggenheim upgrades Editas Medicine stock rating on gene editing therapy By Investing.com
Guggenheim has upgraded Editas Medicine (EDIT) from Neutral to Buy, setting a price target of $5.00, driven by the promising preclinical data for its gene editing therapy, EDIT-401. This therapy, aimed at severe hypercholesterolemia, demonstrated significant reductions in LDL-C and ApoB, leading to a 7.75% stock jump over the past week and a 42% year-to-date gain. Editas Medicine plans to initiate a Phase 1/2a clinical study for EDIT-401 in Q4 2026, targeting a niche market of ASCVD patients with highly elevated LDL-C.
Guggenheim Upgrades Editas Medicine to Buy From Neutral, Price Target is $5
Guggenheim has upgraded Editas Medicine (EDIT) to a "Buy" rating from "Neutral," setting a new price target of $5. The article mentions that Editas Medicine currently has an average analyst rating of overweight with a mean price target of $4.88. Access to the full report requires a premium subscription.
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
Editas Medicine plans to begin patient dosing in 2026 for its lead gene-editing therapy, EDIT-401, targeting high LDL cholesterol. This in vivo CRISPR therapy aims to increase LDL receptor production, with non-human primate studies showing a 90% reduction in LDL cholesterol. The company, which had $212 million in cash as of Q2, expects initial safety data in Q1 2027 and broader results later that year, anticipating funding operations into the second half of 2028.
Opaleye Management Inc. Buys 1,934,933 Shares of Editas Medicine, Inc. $EDIT
Opaleye Management Inc. significantly increased its stake in Editas Medicine, Inc. (NASDAQ:EDIT) during the second quarter, purchasing 1,934,933 additional shares to own a total of 3,861,930 shares, valued at approximately $12.5 million. This investment now represents 2.51% of Editas Medicine and 1.1% of Opaleye Management's portfolio. Editas Medicine, a clinical-stage biotechnology company, maintains a "Moderate Buy" consensus rating from analysts, with an average target price of $6.00, and recently surpassed quarterly revenue and EPS estimates.
Editas Medicine grants stock options to new chief medical officer
Editas Medicine Inc. (NASDAQ:EDIT) has granted stock options to Daniel Ory upon his appointment as Chief Medical Officer. Dr. Ory received options to purchase 950,000 shares at $3.03 per share, vesting over four years. This inducement award aligns with Nasdaq Listing Rules, reinforcing the company's commitment to its gene editing technology development.
Editas Medicine, Inc. SEC Filing (Sep 9, 2026)
This article reports on an SEC filing by Editas Medicine, Inc. (EDIT) dated September 9, 2026. The filing is a Notice of Effectiveness for Form S-3, indicating the SEC has declared a registration statement effective. The article also provides recent news and SEC filings for Editas Medicine, along with key stock data.
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
Editas Medicine is preparing to initiate the first human trial in Australia for EDIT-401, a CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia. The therapy, delivered via a single intravenous infusion, has shown promising results in non-human primates, significantly reducing LDL cholesterol and increasing LDL receptor expression. The company expects to share human safety data in Q1 2027 and initial efficacy results later that year, with sufficient cash reserves to fund development into the second half of 2028.
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
Editas Medicine announced the grant of an inducement award to its new Chief Medical Officer, Daniel Ory, M.D. This award includes a stock option to purchase up to 950,000 shares of Editas Medicine common stock at $3.03 per share, vesting over four years. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for Dr. Ory's employment.
Editas Medicine Appoints Dan Ory as Chief Medical Officer
Editas Medicine, Inc. has appointed Dan Ory, M.D., as Chief Medical Officer to lead its clinical development strategy and operations. Ory brings over 25 years of experience in cardiovascular and genetic medicine and will focus immediately on advancing the company's lead EDIT-401 program for hyperlipidemia into clinical trials. His appointment strengthens Editas's leadership as it shifts towards in vivo gene editing and expands into broader disease areas like cardiovascular medicine.
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Editas Medicine has appointed Dan Ory, M.D., as its new Chief Medical Officer, effective immediately. Dr. Ory brings over 25 years of experience in biotechnology leadership, cardiovascular medicine, and genetic medicine development. In his new role, he will oversee the company's clinical development strategy, particularly focusing on advancing EDIT-401 for hyperlipidemia towards clinical trials and progressing the broader pipeline.
Editas Medicine names Dan Ory as chief medical officer
Editas Medicine (NASDAQ: EDIT) has appointed Dan Ory, M.D., as its new Chief Medical Officer. Dr. Ory brings over 25 years of experience in biotechnology and medicine, and will be responsible for the company's clinical development strategy, particularly for EDIT-401, a gene-editing candidate for hyperlipidemia. His background includes leadership roles at Arbor Biotechnologies and Casma Therapeutics, as well as a significant tenure at Washington University School of Medicine.
Editas Medicine names Dan Ory as chief medical officer By Investing.com
Editas Medicine, Inc. has appointed Dan Ory, M.D., as its new Chief Medical Officer, effective immediately. Dr. Ory brings over 25 years of experience in biotechnology and genetic medicine, and will be responsible for the company's clinical development strategy, including advancing its lead candidate EDIT-401 for hyperlipidemia. He previously held CMO positions at Arbor Biotechnologies and Casma Therapeutics, and was a professor at Washington University School of Medicine.
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Editas Medicine has announced the appointment of Dan Ory, M.D., as its new Chief Medical Officer, effective immediately. Dr. Ory brings over 25 years of experience in biotechnology leadership, cardiovascular medicine, and genetic medicine development. In his new role, he will oversee the company's clinical development strategy, particularly focusing on advancing EDIT-401 for hyperlipidemia and progressing the broader pipeline.
A potential gene-editing treatment moves toward trials as Editas adds a veteran with more than 25 years' experience.
Editas Medicine (EDIT) has appointed Dan Ory, M.D., as Chief Medical Officer, effective September 8, 2026, to lead its clinical development organization. Dr. Ory brings over 25 years of experience in biotechnology leadership, cardiovascular medicine, and genetic medicine development. He will oversee clinical strategy and operations as Editas advances EDIT-401, its lead in vivo gene editing candidate for hyperlipidemia, toward first-in-human studies.
Seven Fleet Capital Management LP Takes Position in Editas Medicine, Inc. $EDIT
Seven Fleet Capital Management LP has acquired a new position in Editas Medicine, Inc. (NASDAQ:EDIT), purchasing 1.33 million shares valued at $4.31 million. This makes Editas Medicine its 28th largest holding, representing 0.7% of the fund's portfolio. Institutional ownership in Editas Medicine remains high at 71.9%, with other firms also increasing their stakes, while analysts maintain a "Moderate Buy" rating with a $6.00 price target.
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 Shares of Stock
Editas Medicine CEO Gilmore Neil O'Neill sold 5,124 shares of the company's stock for $15,576.96 to cover tax obligations from vested equity awards, reducing his ownership by 2.06%. The transaction occurred under a Rule 10b5-1 plan. Despite the sale, the company's stock rose 4.9%, and it recently beat analysts' earnings and revenue estimates.
BlackRock Inc. Takes Position in Editas Medicine, Inc. $EDIT
BlackRock Inc. recently acquired a significant stake in Editas Medicine, Inc., purchasing over 10.5 million shares valued at approximately $34.3 million. This acquisition makes BlackRock a major institutional investor, holding about 10.82% of the company's stock. Editas Medicine, a clinical-stage biotechnology company, reported better-than-expected quarterly results despite remaining unprofitable, and analysts maintain a "Moderate Buy" consensus for the stock.
Nantahala Capital Management LLC Acquires Shares of 852,700 Editas Medicine, Inc. $EDIT
Nantahala Capital Management LLC has acquired 852,700 shares of Editas Medicine, Inc. (NASDAQ:EDIT) for approximately $2.76 million, establishing a 0.56% stake in the company. Institutional investors now collectively own 71.90% of Editas Medicine. The biotech firm recently surpassed quarterly earnings expectations and maintains a "Moderate Buy" consensus rating from analysts, despite remaining unprofitable and dependent on clinical and regulatory advancements.
Zacks Research Lifts Earnings Estimates for Editas Medicine
Zacks Research has raised its Q3 2026 EPS estimate for Editas Medicine (NASDAQ:EDIT) to a loss of $0.25 per share, an improvement from its prior estimate of a $0.34 loss, and projects a full-year 2026 loss of $0.90 per share. This positive revision follows Editas Medicine's stronger-than-expected quarterly earnings, where the company reported a $0.15-per-share loss against a consensus of $0.27 and revenue of $11.89 million, significantly surpassing estimates of $2.85 million. The stock maintains a "Moderate Buy" consensus rating with a $5.50 price target, and institutional investors hold 71.9% of shares.
1,330,500 Shares in Editas Medicine, Inc. $EDIT Bought by Seven Fleet Capital Management LP
Seven Fleet Capital Management LP recently acquired 1.33 million shares of Editas Medicine, Inc. (NASDAQ:EDIT), valued at approximately $4.31 million, making it their 27th largest position. Other institutional investors have also adjusted their holdings, and insider activity shows a CEO share sale. Analysts maintain a "Moderate Buy" consensus with an average price target of $5.50, despite the company remaining unprofitable.
Certain Stock Options of Editas Medicine, Inc. are subject to a Lock-Up Agreement Ending on 25-AUG-2026.
Certain stock options for Editas Medicine, Inc. (EDIT) are subject to a lock-up agreement that ends on August 25, 2026. This lock-up period prevents executive officers and directors from selling or transferring beneficially owned shares or related securities for 90 days, starting from May 26, 2026. This measure is detailed in a prospectus supplement and aims to manage the market impact of new stock availability.
ETFs Investing in Editas Medicine, Inc. Stocks
This article provides a list of Exchange Traded Funds (ETFs) that hold Editas Medicine, Inc. stocks, sorted by market value. It details various ETFs, including those from BlackRock, Vanguard, and Invesco, highlighting their management style, focus, expense ratio, assets under management (AUM), and performance metrics. The information aims to help investors identify ETFs with exposure to Editas Medicine, Inc. for diversified investment opportunities.
Editas Medicine (NASDAQ:EDIT) Trading 14.4% Higher - Here's What Happened
Editas Medicine (NASDAQ:EDIT) shares surged 14.4% to $3.30, with approximately 1.74 million shares traded. The company surpassed quarterly expectations, reporting an adjusted loss of $0.15 per share against an estimated $0.27 loss, and revenue of $11.89 million compared to a $2.85 million forecast. Analyst sentiment remains largely positive, holding a "Moderate Buy" consensus rating and an average price target of $5.50.
EDIT Initiates Coverage On Ladenburg Thalmann - Rating Set to Buy
Ladenburg Thalmann has initiated coverage on Editas Medicine (EDIT) with a Buy rating and a price target of $6.00, according to GuruFocus. Despite this positive analyst outlook, GuruFocus indicates that EDIT is currently overvalued by 23.5% with a GF Value of $2.30 compared to its current price of $2.84, and has a moderate GF Score of 58/100 due to strong momentum but poor profitability. Investors are advised to proceed with caution given the high price-to-sales ratio and mixed insider activity.
Editas Medicine (NASDAQ:EDIT) Coverage Initiated at LADENBURG THALM/SH SH
LADENBURG THALM/SH SH initiated coverage on Editas Medicine (NASDAQ:EDIT) with a "buy" rating and a $6.00 price target, representing a potential upside of over 111%. This follows Editas Medicine reporting quarterly revenue of $11.89 million and an adjusted loss of $0.15 per share, significantly exceeding analyst expectations. The company currently holds an average rating of "Moderate Buy" from analysts, with institutional investors owning a substantial 71.90% of the stock.
367,147 Shares in Editas Medicine, Inc. $EDIT Bought by GSA Capital Partners LLP
GSA Capital Partners LLP has acquired a new stake of 367,147 shares in Editas Medicine, Inc. (NASDAQ:EDIT), valued at approximately $1.19 million, representing about 0.37% of the company. Other institutional investors have also increased their holdings, while company insiders have sold some shares. Editas Medicine, a clinical-stage biotechnology company, reported stronger-than-expected earnings for the last quarter and holds a "Moderate Buy" consensus rating from analysts with a target price of $5.40.
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Moderate Buy" by Analysts
Editas Medicine (NASDAQ:EDIT) has received an average rating of "Moderate Buy" from analysts, with four out of six recommending a buy, one a hold, and one a sell. The average 12-month price target is $5.40, significantly higher than its recent trading price of $2.82. The company, which focuses on CRISPR-based treatments, exceeded quarterly revenue and EPS estimates but remains unprofitable with a negative net margin.
Editas Medicine (EDIT): ADAR1 Capital and Schneeberger disclose 5.8% ownership
ADAR1 Capital Management, LLC and its manager Daniel Schneeberger have disclosed a beneficial ownership of 5.8% in Editas Medicine, Inc. This stake, totaling 8,889,000 shares, is held by private investment funds managed by ADAR1 Capital Management. The filing indicates shared voting and dispositive power over these shares, with Mr. Schneeberger acting as a control person for the investment adviser.
Weekly Recap: Editas Medicine, Inc. Q2 results and EDIT-401 Australia CTN
Editas Medicine, Inc. reported a net loss of $18.2M and revenues of $11.9M for Q2 2026, with cash reserves sufficient until H2 2028. The company is advancing its EDIT-401 program by filing an Australian CTN to initiate a Phase 1/2 trial for HeFH in Australia and New Zealand, with topline data expected in 2027.
HC Wainwright Boosts Earnings Estimates for Editas Medicine
HC Wainwright has revised its earnings estimates for Editas Medicine, projecting narrower losses for fiscal years 2026 and 2027. Despite the improved forecasts, the gene-editing company is still expected to remain unprofitable through 2027. Editas Medicine recently surpassed analyst expectations for its quarterly earnings and revenue, while insider transactions show some selling activity from the CEO.
Wall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to Hold
Wall Street Zen has upgraded Editas Medicine (NASDAQ:EDIT) from "sell" to "hold." Despite this, broader analyst coverage remains "Moderate Buy" with a consensus price target of $5.40. The company recently surpassed quarterly earnings and revenue expectations, although company insiders have sold shares while institutional investors, including BlackRock, have significantly increased their holdings.
Editas Medicine director Ellinor Patrick Thomas II files initial beneficial ownership statement
Editas Medicine director Ellinor Patrick Thomas II has filed an initial beneficial ownership statement (Form 3) with the SEC, dated August 6. This filing indicates that Thomas is now a reporting owner for the company. The news brief was generated by Public Technologies (PUBT) using AI and is based on original content filed by Editas Medicine Inc. via EDGAR.
Editas Medicine, Inc. (EDIT) director reports no share or option holdings
A director at Editas Medicine, Inc. (EDIT), Ellinor Patrick Thomas II, has filed an initial beneficial ownership report (Form 3) disclosing no holdings of common stock or derivative securities. The filing indicates no insider transaction activity, such as purchases or sales, associated with this individual. Ellinor Patrick Thomas II is identified solely as a director, not as an officer or a ten percent owner.
Editas Medicine (NASDAQ: EDIT) grants director 103400 options at $2.9000
Editas Medicine (NASDAQ: EDIT) reported that director Ellinor Patrick Thomas II was granted 103,400 stock options with an exercise price of $2.9000 per share, expiring on August 5, 2036. These options vest in three equal annual installments starting August 6, 2027. Following this grant, the director directly holds 103,400 derivative securities.
Editas Medicine (EDIT) Stock Rallies On Revenue Jump But Losses Linger
Editas Medicine (EDIT) saw its stock rally by about 5% after reporting Q2 2026 earnings, driven by a significant increase in revenue to US$11.89 million from US$3.58 million year-on-year. While the company is still reporting losses, these narrowed to US$18.23 million from US$53.24 million, and basic EPS loss decreased to US$0.15 from US$0.63. Despite this positive momentum, the article notes that funding risks and volatility remain concerns for the clinical-stage biotech.
Editas Medicine, Inc. 2026: Revenue $11.89M, EPS ($0.15) — 10-Q Summary
Editas Medicine, Inc. reported an increase in collaboration and research revenue to $11.89M for the quarter ended 2026, with a reduced net loss of ($18.23M) and improved diluted EPS of ($0.15). Key highlights include the nomination of EDIT-401 as the lead in vivo candidate with a Phase 1/2 trial planned, and successful equity offering to fund operations into the second half of 2028. The company has also narrowed its R&D priorities and completed workforce reductions.
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
Editas Medicine (EDIT) reported a narrower-than-expected loss of 15 cents per share in Q2 2026, with revenues significantly surpassing estimates at $11.9 million due to deferred revenues. The company's lead gene-editing candidate, EDIT-401, for heterozygous familial hypercholesterolemia, showed encouraging preclinical data with rapid and durable LDL cholesterol reductions in non-human primates. Editas plans to submit a Clinical Trial Notification in Australia in August 2026 to initiate a phase I/II study for EDIT-401, with data updates expected in Q1 2027 and top-line results later in 2027.
Press Release: Editas Medicine Announces Second Quarter 2026 Results and Business Updates
Editas Medicine (NASDAQ: EDIT) announced its second quarter 2026 financial results and provided business updates. The company highlighted recent progress in its CRISPR-based therapeutic programs and discussed its financial position, offering insights into its strategic direction and upcoming milestones for the remainder of the year.
Editas Medicine (NASDAQ:EDIT) Issues Earnings Results
Editas Medicine (NASDAQ:EDIT) announced its quarterly earnings, reporting an adjusted loss of $0.15 per share, surpassing the consensus estimate of a $0.27 loss, with revenue of $11.89 million, significantly exceeding analyst expectations of $2.85 million. Despite beating revenue and EPS estimates, the company remains unprofitable and its stock traded down 0.5% to $2.75. Analyst sentiment is mixed but leans positive, with a "Moderate Buy" rating and an average price target of $5.40.
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
Editas Medicine (EDIT) reported a Q2 loss of $0.15 per share, surpassing the Zacks Consensus Estimate of a $0.3 loss and representing a 50% surprise. The company also beat revenue estimates with $11.89 million, significantly higher than the $3.58 million from the previous year. Despite outperforming the market year-to-date, Editas currently holds a Zacks Rank
Editas Medicine (Nasdaq: EDIT) equity deal lifts cash to $211.6M
Editas Medicine reported a Q2 2026 net loss of $18.2 million, significantly trimmed from $53.2 million a year prior, and saw collaboration revenues increase to $11.9 million. The company's cash, cash equivalents, and marketable securities totaled $211.6 million as of June 30, 2026, boosted by a May 2026 equity offering that raised $116.9 million in net proceeds. Editas Medicine expects this liquidity to fund operations for at least the next twelve months and is focusing resources on its EDIT-401 program for heterozygous familial hypercholesterolemia, with initial patient data anticipated in 2027.
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
Editas Medicine reported its Q2 2026 financial results and provided business updates, highlighting the advancement of its gene editing program, EDIT-401, for hyperlipidemia. The company
Editas Medicine (EDIT) CFO tax-related share sale executed under preset plan
Editas Medicine's CFO, Amy Parison, sold 678 shares of common stock at $2.58 per share on August 3, 2026. This transaction was executed under a pre-established Rule 10b5-1 plan to cover tax withholding obligations from restricted stock units that vested on August 1, 2026, and was not a discretionary trade. Following the sale, Parison directly holds 14,292 shares of Editas Medicine common stock.
